top of page

About Our Study

Our research team is focused on identifying patients with transthyretin cardiac amyloidosis (ATTR-CA) as soon as possible before signs and/or symptoms develop. Early diagnosis is key to best leveraging therapies for ATTR-CA as they work better early in the course of the illness. We are using previously obtained lumbar spine stenosis specimens for identification of individuals who may have ATTR-CA. With funding from the NIA, our study could change clinical practice by allowing for early identification of those who develop this disorder. Without recognition and treatment, transthyretin cardiac amyloidosis is a progressive, highly morbid, and fatal disease. However, with early identification, it is easily managed.

About Our Team

Our team of researchers, clinicians and pathologists is committed to advancing our understanding of transthyretin cardiac amyloidosis and finding new ways to diagnose and treat this disorder. We are a diverse group of individuals with different backgrounds and areas of expertise, but we share a common goal: to make a difference in the lives of those affected by transthyretin cardiac amyloidosis. 

bottom of page